JPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10<blockquote>摩根大通将 Recursion Pharmaceuticals 评级从中性上调至跑赢大盘,将 PT 从 10 美元调整至 11 美元</blockquote>
Recursion Pharmaceuticals (RXRX) has an average rating of overweight and mean price target of $7, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f